












Designing and incorporating a real
world data approach to international
drug development and use: what the
UK offers
Andrew Bate1,2, andrew.bate@pfizer.com, Jane Juniper3,4, Andy M. Lawton5 and Rob M.A. Thwaites6
Assessments of the safety, efficacy and appropriate use of new medicines lie at the heart of treatment
development and subsequent adoption in clinical practice. Highly controlled randomised clinical trials
routinely inform decisions on the approval, coverage and use of a medicine. Researchers and decision
makers have become increasingly aware that these experimental data alone are insufficient to address
those decisions fully. Real world data recorded from routine healthcare delivery by healthcare
professionals and patients help provide a more complete picture of care. The UK, with its connectivity
and rich longitudinal patient records, accumulated research and informatics experience and National
Health Service, provides an exemplar of how real world data address a wide range of challenges across
drug development.
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Real world data (RWD) have been defined simply
as ‘data used for decision-making that are not
collected in conventional randomised clinical trials
(RCTs)’ [1]. RWD are characterised by very large
(relative to RCTs), complex, intricately structured
datasets, with several years of data on millions of
patients. The National Health Service (NHS) is a
near monopoly provider to UK residents and
visitors of primary healthcare, through a network
of contracted general practitioners, and secondary
healthcare, provided by wholly state-owned hos-
pitals. General practitioners are the gatekeepers of
the healthcare system because they are the rou-
tine first point of entry into the healthcare system,
referring patients as needed for more-specialist
treatment; and electronic medical records (EMRs)400 www.drugdiscoverytoday.com
1359-6446/ 2015 provide a detailed record of primary care inter-
actions as well as insights into referrals to and from
other healthcare delivery systems. As software
increasingly were introduced in surgeries for
medical record storage in electronic format the
same software systems meant that with appro-
priate safeguards and caveats large numbers of
inter-surgery EMRs could be stored in databases,
and used in anonymised format by external parties
for research. For example, one such dataset in the
UK, the Clinical Practice Research Datalink (CPRD)
[2], formerly known as the General Practice Re-
search Datalink (GPRD) [3], has data now on over
15 million patients contributing over 82 million
years of prospectively collected longitudinal data –
more than 5 years of history per patient on average
with more than 3.5 million patients who have moreThe Authors. Published by Elsevier Ltd. This is an open access article unthan 10 years of history (Williams, T., personal
communication). Copies of real-world healthcare
data from other sources, also originally collected
for the clinical care of patients, are stored and
linked in the Health and Social Care Information
Centre (HSCIC) in England, and equivalent bodies
in the rest of the UK. This data confederation serves
as a focus for many epidemiological research
projects in the UK. The near-universal existence of
an NHS number, unique per patient, also facilitates
data linkage across the healthcare systems. Further
information on CPRD and other examples of UK
RWD sources are included in Table 1. We consider a
RWD approach as one that systematically (i) con-
siders which data are required to answer decision
maker questions, (ii) determines whether those
data are available for secondary analysis forder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
http://dx.doi.org/10.1016/j.drudis.2015.12.002
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TABLE 1
Examples of the many hundreds of health data sources in the UK, each distinct in terms of varying size and the type of data that are
captured.
Database Characteristic Population size
Clinical Practice Research Datalink (CPRD; formerly GPRD) General practitioner (GP) primary care database 12+ million patients [3]
The Health Improvement Network (THIN) GP primary care database 10.5 million patients [44]
Hospital Episode Statistics (HES) All patients treated in an English National Health
Service (NHS) hospital. Clinical data and
demographics including hospital in-patient
diagnoses and procedures from the hospitals [45]
Over 125 million patient,
outpatient and accident and
emergency records each year [46]
Cancer screening: National Breast Screening
Programme data
Data on all English women undergoing a
mammography screening, aged between 50 and
70, all of whom are invited every third year, and
other and self referrals [47]
Data on the 1–2 million women
screened per year [48], 1.94 million
women aged 45 and over screened
in the year 2011–2012 [49]
Cancer screening: National Bowel Screening
Programme data
Bowel Cancer Screening System has clinical and
demographic data for English patients screened at
over 59 for bowel cancer, their episode history,
results of their Faecal Occult Blood Testing (FOBT)
tests and diagnostic tests and histology information
[50]
11.2+ million people of age greater
than 59 [50]
The National Cancer Waiting Times (CWT)
Monitoring Data Set
Patients diagnosed with suspected cancer in
England in an NHS hospital setting [51]
865 494 ‘2 week wait referrals’ and
224 984 cancers (from 8049
English practices) [52]
National Cancer Data Repository (NCDR) Information about every patient with cancer
diagnosed in England, obtained from routine NHS
data sources. Created by linking cancer registry and
HES data [22]
Data on 114 155 patients
underwent major resection for a
colorectal tumour over a 5 year
















Ehealthcare applications and, if so, (iii) looks to find
an effective way to collect, access and analyse
those data. We consider the conduct of pure
primary data collection studies out of scope for this
manuscript and instead focus on analyses of
routinely collected healthcare data. We present
case studies from the UK that show how a RWD
approach can and is being adopted and how it
might transform decision maker evaluations.
Although we focus here on the UK, interna-
tionally there are many RWD sources, each
dataset with its own strengths and weaknesses
associated with the underlying healthcare sys-
tem. For example, the fragmented nature of the
US healthcare system means it can be difficult to
follow patients across care providers. In addition,
data are captured primarily for billing purposes
rather than healthcare provision which means
important research data such as laboratory test
results are often not captured. Databases in
Scandinavia and Scotland are rich and link reli-
ably across the healthcare system (the ubiqui-
tous existence and use of a personal ID number
in, for example, Sweden facilitates this) but can
be too small for some research questions, be-
cause the population of these countries is rela-
tively small compared with England and the USA.
In recent years an increasing number of studies
have been performed synthesising RWD from
different healthcare organisations or countries,often motivated by the need to improve statistical
power [4]. To facilitate the RWD approach in this
context, there are several within, and across,
country initiatives: examples include the US Sen-
tinel Initiative and Observational Medical Out-
comes Partnership (OMOP); the Canadian
CNODES; the pan-Asian network Asian Pharma-
coepidemiology Network (ASPEN); and European
initiatives such as Innovative Medicines Initiative’s
Pharmacoepidemiological Research on Outcomes
of Therapeutics (IMI PROTECT) and European
Union-Adverse Drug Reaction (EU-ADR) [5–10]. It is
beyond the scope of this article to provide a
comprehensive list of databases, database net-
works or inter-database comparative analyses; for
more information about database selection see for
example [11,12]. We merely argue that the UK, with
the NHS and its existing data and capabilities, is an
ideal location for a RWD approach and UK RWD
can and should play an even more extensive part
in global drug development [13,14].
Case study: psoriasis and the risk of
chronic kidney disease – the association
between the diseases and the implications
for therapy development and healthcare
policy
A group of US-based researchers (Wan et al.) [15]
describe a study examining the risk of chronic
kidney disease in patients with psoriasis. A keychallenge for this study was to characterise the
level of severity of the psoriasis accurately. Body
surface area direct measurement had previously
been shown to be a good estimate of psoriasis
severity, but is not a measure routinely captured
in records. EMRs sometimes cannot adequately
capture severity directly nor its fluctuations ac-
curately, often relying on proxy measurement,
see for example [16,17]. The authors prospec-
tively collected data from general practitioners
(GPs) on a subset of patients in a UK EMR
database called The Health Improvement Net-
work (THIN). This cohort, called the Incident
Health Outcomes and Psoriasis Events (iHOPE24)
study, had disease severity for 10 500 patients
aged 25–64, based on extent of body surface
area affected by psoriasis.
The iHOPE24 cohort was then used to show
that treatment patterns correlated with body
surface area psoriasis coverage, and that treat-
ment patterns could therefore be used for esti-
mating psoriasis severity. Treatment patterns
were then used as a proxy of disease severity for
patients across the full THIN dataset, where data
on body surface area coverage were normally
absent, so that the full power and generalisa-
bility of THIN data could still be used for infer-
ence. The authors reported an increased risk of
incident chronic kidney disease in psoriasis
sufferers but in particular in the severe psoriasiswww.drugdiscoverytoday.com 401












Egroup. With adjusted hazard ratios (95% confi-
dence intervals) for incident chronic kidney
disease of 1.93 (1.79–2.08), the risk also varied
with age. The longitudinal prospective nature of
large-scale rich data collection as part of routine
healthcare meant that the authors were able to
account for and remove the impact of diabetes,
hypertension and nephrotoxic drug use which
had not been possible in previous studies. Wan
et al. [15] felt able to conclude that all patients
presenting with moderate-to-severe psoriasis
(based on body surface area) should be screened
for renal insufficiency, thereby providing a jus-
tification for earlier treatment. The key factor in
being able to conduct the study was the
strength of the underlying EMR resource: the
quality of the data, the extent of the database
and the ability to access patients for the missing
information.
Case study: understanding the true clinical
and cost impact of medicine use in
everyday healthcare – the Salford Lung
Study
In the Salford Lung Study (SLS) [18], ongoing at
the time of writing, GlaxoSmithKline (GSK) used a
RWD approach to establish evidence for a novel
agent used in the treatment of chronic ob-
structive pulmonary disease (COPD) and asthma.
The vision at the outset was that GPs could first
select patients for the trial based on their EMR
then, after giving informed consent, some
patients would be prescribed the experimental
drug and some would take their usual medicine
– the standard of care (SOC). Then, after a year,
during which the patients would visit their GP or
nurse when required, information on the out-
comes would be extracted from the computer
systems and a statistical comparison could be
made to inform the recommendation on cov-
erage and effectiveness.
The key to the selection of research design
was the realisation that outcome data for any
patient treated in the NHS would exist in com-
puter systems of the English GPs, hospitals and
pharmacies. Furthermore, as New et al. [4] point
out, the RWD approach for this particular disease
area is particularly apt because few patients
meet the standard eligibility requirements of a
controlled clinical trial.
GSK and study partners discussed the study
with the Medicines and Healthcare Products
Regulatory Agency (MHRA) and the National
Institute for Health and Care Excellence (NICE)
via their joint scientific advice procedure. The
study was subject to the usual regulatory and
ethical requirements for traditional clinical trials.
In this example, the RWD approach had the402 www.drugdiscoverytoday.compotential to benefit patients by allowing reim-
bursement agencies better data sooner than
would have been the case with a traditional
controlled trial.
To maintain confidentiality of patient data and
avoid disruption to normal care in this novel study
approach, purpose-built, multi-tiered, security
and governance processes had to be developed.
Specifically, potential adverse events experienced
by patients had to be captured, reviewed in the
context of the patient care record and reported to
the regulatory agency. The RWD approach en-
sured that these data were collected in routine
practice, but it was necessary to build interfaces
between systems to transmit the information
accurately [19]. There were semantic challenges
because outcomes were defined differently in the
study than in the routine clinical systems. To
address these, an electronic case report form
(eCRF) ran in parallel with the EMR, so the SLS was
really a hybrid of the normal drug development
trial and the type of innovative engagement
required to anchor the study in RWD.
The UK system of universal healthcare anal-
ogous to a single health plan, to which the entire
population is effectively enrolled at birth, lends
itself well to projects like this. Researchers
adopting the RWD approach work with a single
organisation and the data describing the Health
Outcome of Interest (HOIs) exist in the systems of
that organisation. Implementation is nontrivial,
for example over 200 people were employed to
make the study of 7000 COPD patients and 4237
asthma patients operational but these costs
should be recoverable as the system is honed,
reused and extended.
Case study: diagnosing cancer and the
impact it has on survival times – the
implications for patients and healthcare
policy
Survival rates in cancer in England are worse than
in many other European countries and studies
have demonstrated that late diagnosis is often the
cause [20]. To explore this with data from England,
Elliss-Brookes et al. [21] analysed different routes to
diagnosis. Following a RWD approach, they re-
trieved information for 739 667 tumours from four
different databases: (i) hospital episode statistics;
(ii) cancer waiting times; (iii) cancer screening
programmes; and (iv) cancer registration data from
the National Cancer Data Repository (NCDR) [22],
linkage conducted through the NHS number,
unique to each individual in England.
Although estimated one year survival time
measured from the date of diagnosis was the key
overall metric, the route to diagnosis needed to
be explored and the data organised in such away that this could be identified. The linked data
enabled the circumstances of the diagnosis to be
categorised. The study identified eight catego-
ries of which three reflected an emergency. An
algorithm was developed to search for data to
attribute each patient to one of the eight cate-
gories. Analysis of the linked data demonstrated
that for every tumour type the one year relative
survival was significantly lower following an
emergency presentation. In January 2015 NHS
England and London Cancer announced [23] a
new programme to diagnose cancer more
quickly at over 60 sites across England, by fo-
cusing on prevention, earlier diagnoses and in-
novative treatments and services, they
estimated 8000 more lives per year from cancer
could be saved.
Case study: the use of RWD in economic
evaluations
In the UK, RWD have been used in many eco-
nomic evaluations of new technologies. There
are many bodies undertaking appraisals of new
technologies, with NICE probably the most well-
known and the most widely referenced by
similar agencies in other countries. Where, for
example, economic models have been submit-
ted to NICE to demonstrate the cost-effective-
ness or expected budget impact of new
technologies, RWD reflecting clinical practice,
resource use and costs in UK settings have been
necessary components. These data might have
been collected in a purpose-designed study,
extracted from sources of anonymised electronic
records or derived from published sources.
NICE has been clear on the importance of
RWD in its appraisals of new technologies and
development of recommendations and guide-
lines for treatment. In his 2006 Harveian Oration,
Professor Sir Michael Rawlins, then Chair of NICE,
stressed that decision makers ‘. . .need to assess
and appraise all the available evidence irre-
spective of whether it has been derived from
randomised controlled trials or observational
studies; and the strengths and weaknesses of
each need to be understood if reasonable and
reliable conclusions are to be drawn’. Observing
that clinical trials have long been placed at the
head of hierarchies ranking the quality of evi-
dence, he asserted that ‘. . .the notion that evi-
dence can be reliably placed in hierarchies is
illusory’ [24]. With the increasing emphasis that
NICE places on RWD in assessing effectiveness
and cost-effectiveness, and the influence that
NICE appraisals have on assessments in countries
around the world [25], RWD collected in the UK
have an impact beyond the national and local
settings.
Drug Discovery Today  Volume 21, Number 3 March 2016 PERSPECTIVEThe importance of updating cost-effective-
ness analyses for a new product built largely on
clinical trial data to incorporate experience with
the product in clinical practice has been raised in
several papers [26,27]. The paper by van Staa
et al. [27], reviewing the use and value of se-
lective cyclooxygenase (COX)-2 inhibitors in the
UK, showed that results – and therefore
assessments of the value of a product – are
sensitive to new information on use of a drug in
practice. Detailed patient-level data are now
available that allow such reassessments to be
made. Linkage of dispensing data to the cur-
rently available prescribing data will allow a
better assessment of adherence in the foresee-
able future, but newer technologies will be
needed for tracking of compliance following
dispensing. Once these data are available, a
more detailed understanding of what drives
cost-effectiveness beyond the clinical setting will
be possible.
Concluding remarks
Any country with a digitised healthcare record
system could, in principle, be used as a location
for the conduct of RWD studies as part of a
global drug research programme. There is in-
creasing availability and use of RWD around the
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Examples of issues that real world data (RWD) can addr
PhIII, Phase III; TPP, target product profile.particular [28] has a strong track record and key
characteristics for high-quality RWD research.
Furthermore RWD from the UK can be used
extensively in global drug development activi-
ties (Fig. 1), and in national and local decisions on
access to medicines and healthcare utilisation.
This quality of UK data arises from the numbers
of patients whose EMRs are already available for
research, from the extent of and long histories in
the records, and from the connectivity of the UK
healthcare system which, taken together, are
unmatched. Additionally, because the RWD ap-
proach is well established, particularly around
the use of primary care EMRs [29,30], a corre-
sponding mature research culture has devel-
oped. This is evident from the commercial and
academic centres [31] specialising in informatics,
epidemiology and statistics rooted in the NHS
systems and data.
Use of the RWD approach is challenging.
Often the data are hard to find, the quality can be
limited and linkage can be difficult. Incorpo-
ration of additional data from outside the health
service such as social media and patient-gen-
erated data will pose fresh challenges. Computer
systems could face interoperability issues.
Inconsistencies with coding in data capture can
sometimes present issues with interpretation.
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early use of the 
drug in practice?  
ess at the different stages of the drug development lifecexisting datasets, particularly primary care, is
relatively well established and often rapid, it is
less clear or timely for data originating in spe-
cialist care. These issues are recognised at UK
government level and are being addressed
[32–34].
Studies using RWD are not suitable for many
aspects of drug development and will not en-
tirely replace the controlled experiments, in-
cluding clinical trials, as tools for testing
hypotheses or understanding the underlying
mechanisms of disease and treatment. They
often represent a complement rather than a
replacement to RCTs, addressing different
questions or providing results more likely to
generalise to routine healthcare scenarios, see
for example [35–37]. The examples herein make
the case for more active consideration of RWD
for many types of questions encountered during
the development and application of a new
medicine. However, use of RWD requires a clear
understanding of decision maker evidence
needs, a supportive legal and healthcare archi-
tecture, an expert knowledge of the semantics of
the data and sufficient analytical and computing
resources to convert the data into the evidence
needed.
Although there remains a dearth of clear
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Epolicy, this is we believe primarily caused by two
factors. Firstly, there are a multitude of issues that
influence policy and frequently it is hard to link a
policy decision to results from a specific study;
and secondly there is a lack of literature on
systematic studies specifically assessing the
impact of studies on assessment and therefore
potentially policy. One such example of the latter
is the study of Vermeer et al. [38] which looked
prospectively at the impact of studies in risk
management planning on changes to the as-
sessment of risk. Although some risk assessment
changed, many had not at the time of study,
which the authors attributed to the long delay
from study initiation to completion and any
subsequent policy change. Given that the use of
RWD analyses is relatively new, it would seem
reasonable to assume that there will be a rapid
increase in evidence as to the value of RWD
analyses in the not too distant future. Current
attempts to translate RWD into decision making
include the Map of Medicine1 [39]: an online
resource that looks to make data available in an
actionable format to clinical decision makers
(http://mapofmedicine.com/about/).
Clearly, further such studies are needed to
measure the impact of the analyses on deci-
sion making and routine care. Guidelines on
best practice with RWD continue to be de-
veloped [40–42] and policy debated in the UK
and elsewhere [1], and such harmonisation on
good practice can be anticipated to further the
positive impact of RWD studies. Furthermore,
with proportionate governance and by en-
suring skill sets are updated [43], for example
to utilise health data collected through social
media and other ‘big data’, the UK remains a
place where the RWD approach to drug de-
velopment can continue to flourish. These case
studies provide examples of, the need for and
case for more extensive appropriate use of
RWD in the UK and elsewhere. Improvements
are continually being made to the evaluation
of new and existing treatments with conse-
quent benefit to patients. The potential of
RWD in adding to these evaluations is signif-
icant – great strides are being made in the
availability and quality of data and in the
associated systems and analytical approaches.
Researchers, decision makers and, most im-
portantly, patients will all reap the benefits of
the additional evidence and insights that RWD
will bring.
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